Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors
Status:
Completed
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
The aim of this study is the safety and efficacy of Bevacizumab plus allogeneic natural
killer (NK) immunotherapy to many kinds of recurrent solid tumors.